This article refers to 'Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomized, placebo-controlled trial' by A. Jorsal et al., published in this issue on pages 69-77.
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The main objective of LIVE was to determine the effect of the long-acting glucagon-like peptide-1 (GLP-1) analogue liraglutide on LV function in patients with chronic heart failure and reduced ejection fraction (HFrEF) and with or without type 2 diabetes mellitus.
A promising background
Glucagon-like peptide-1 is an endogenous incretin hormone which improves insulin sensitivity and is associated with low risk of hypoglycaemia, and several GLP-1 analogues are approved for the treatment of diabetes mellitus. 2 Abnormal myocardial metabolism has been documented in heart failure, with reduced fatty acid oxidation and myocardial insulin resistance. 3, 4 Experimental studies suggest that recombinant GLP-1 increases myocardial insulin sensitivity and is cardioprotective, whereas a small pilot study suggested that it improves cardiac function in patients with advanced heart failure.
5 -7
Disappointing results
Unfortunately, LIVE failed to show any improvement in EF after 24 weeks of exposure to liraglutide (primary objective) and there was no change in LV dimensions, NYHA class, or quality of life. Moreover, there was a non-significant trend for LV dilation in liraglutide-treated patients. Liraglutide improved glycaemic control, induced a significant weight loss, and systolic blood pressure was slightly decreased, as previously shown with GLP-1 analogues.
The lack of improvement in cardiac function was observed equally in patients with and without diabetes mellitus. Finally, more serious cardiovascular effects were observed in the GLP-1 analogue-treated patients.
A significant increase in heart rate
One plausible explanation for the lack of benefit in this HFrEF population is the significant increase of 6 b.p.m. observed in patients treated with liraglutide. The positive chronotropic effect of GLP-1 analogues is well documented, although the magnitude of the increase in heart rate is variable across studies and it is presumed to be related to a direct stimulation of GLP-1 receptors in the sino atrial node. 8 The association of increased heart rate with poor outcomes is well documented in HFrEF, and each 5 b.p.m. increase was associated with a 16% increase in the occurrence of the primary composite endpoint in a trial testing ivabradine, a pure heart rate-lowering agent in HFrEF, whereas reducing heart rate with this agent was associated with a reverse remodelling and an improvement of EF.
9,10 The significant increase in heart rate induced by liraglutide in the HFrEF population tested in LIVE is therefore a matter of concern.
Lessons from other clinical trials with GLP-1 analogues
Moreover, the unfavourable results observed in LIVE are not stand-alone findings: in a population with recent hospitalization for heart failure (30% with type 2 diabetes mellitus) the FIGHT trial failed to demonstrate any benefit of liraglutide administered once daily as in LIVE on a primary endpoint made up of a global rank score including death, heart failure re-hospitalization, and change in NT-proBNP from baseline to 180 days. 11 Moreover, there was a strong signal for harm when the composite of death or re-hospitalization for heart failure was evaluated, and the point estimates suggested a higher risk in patients with diabetes mellitus than in the overall population.
Are these findings inconsistent with those of LEADER, a large outcome study which enrolled 9340 type 2 diabetic patients at high cardiovascular risk randomized to liraglutide administered subcutaneously once daily or placebo?
In LEADER, the primary endpoint (cardiovascular death/non-fatal myocardial infarction or non-fatal stroke) occurred in significantly fewer patients in the liraglutide group than in the placebo group, whereas the number of heart failure hospitalizations was reduced non-significantly in the active arm.
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However, the LEADER population differs markedly from the patients enrolled in LIVE and in FIGHT: all patients had type 2 diabetes mellitus and only 18% were reported to have heart failure at baseline. In addition, there was no determination of cardiac function and it is likely that a substantial proportion of the patients with heart failure at baseline had preserved EF, a condition in which the effect of GLP-1 analogues is unknown. Moreover, in LEADER, liraglutide increased heart rate by only 3 b.p.m. on average. However, the pre-specified subgroup analysis suggests that the magnitude of the benefit of liraglutide is lower, although not significantly, in patients with a history of heart failure.
The very long-lasting GLP-1 analogue semaglutide administered once weekly was tested in 3297 patients with type 2 diabetes and at high cardiovascular risk in the SUSTAIN-6 trial. 13 The rate of the primary outcome which was identical to that used in LEADER was significantly lower among patients treated with semaglutide than among patients receiving placebo.
In this population, including 24% of patients with a history of heart failure, there was no difference in the rate of heart failure hospitalization between the two groups, but the difference in heart rate was only 2 b.p.m. However, the benefit on the primary outcome seemed to be lower, although not significantly, in patients with a history of heart failure.
In summary, the results of LIVE and the body of existing evidence do not support the use of liraglutide in HFrEF, and they point out the potential harmful effect of the increase in heart rate on cardiac function and cardiac adverse events in this population.
Importantly, the safety of this powerful glucose-lowering agent in patients with diabetes and documented reduced EF remains uncertain. 
